Squarepoint Ops LLC C4 Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

$62.8 Billion
Q3 2024

A detailed history of Squarepoint Ops LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 147,874 shares of CCCC stock, worth $584,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares

147,874

Previous 57,117 158.9%

Holding current value

$584,102

Previous $263,000 220.15%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.43 - $7.38 $402,053 - $669,786	90,757 Added 158.9%	147,874 $842,000
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $322,825 - $645,651	-79,710 Reduced 58.26%	57,117 $263,000
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $481,250 - $998,822	90,802 Added 197.29%	136,827 $1.12 Million
Q4 2023 Feb 14, 2024	SELL	$1.18 - $6.03 $7,078 - $36,173	-5,999 Reduced 11.53%	46,025 $260,000
Q2 2023 Aug 14, 2023	SELL	$2.75 - $3.77 $152,922 - $209,642	-55,608 Reduced 51.66%	52,024 $143,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $164,024 - $477,257	52,911 Added 96.69%	107,632 $337,000
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $181,391 - $342,702	33,467 Added 157.46%	54,721 $322,000
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $123,212 - $195,942	-15,344 Reduced 41.93%	21,254 $186,000
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $103,826 - $542,932	20,519 Added 127.61%	36,598 $276,000
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $61,529 - $102,281	3,078 Added 23.68%	16,079 $390,000
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $382,099 - $609,226	13,001 New	13,001 $419,000

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $193M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC C4 Therapeutics, Inc. Transaction History